INTRODUCTION
The discovery that various of the naturally occurring and synthetic analogues of thyroxine possess some of the many physiological properties of thyroid hormone in variable activity8"", 1416"1725," has stimulated a search for an analogue with the cholesterol-lowering action of desiccated thyroid but without toxic side effects. Such a compound has been sought to decrease the serum cholesterol concentrations of patients with hypercholesterolemia and vascular disease. Thyroxine itself lowers the serum cholesterol but the effect is sustained only when the dosage is raised to concentrations which may produce tachycardia, nervousness, palpitations, or weight loss.'2 Bauer, McGavack, and Swell5 and Rawson, et al.,21 reported a reduction of serum cholesterol in man without increase in basal metabolic rate by the administration of 3, 5, 3'-triiodothyropropionic acid, an analogue of thyroxine referred to here as TRIPROP. Other lipid parameters were not measured, and long-range studies have not been reported.
The present study was undertaken to determine the effect of TRIPROP$ on serum lipids when administered to normal persons in large doses for a short period of time and when given for longer periods to patients with elevated concentrations of serum lipids. The effect of TRIPROP on serum triglyceride concentration was of particular interest in relation to the increased serum triglycerides in coronary artery disease.8" In short-term experiments, large amounts of TRIPROP were given to obtain a maximal effect of the drug on serum lipids, particularly on plasma-free fatty acids, a fraction of plasma lipids which has been found to be important in mobilization of fat from depots.7" In the long term experiments small initial doses of TRIPROP were increased gradually to avoid possible toxic effects to patients with overt or incipient coronary artery disease. TRIPROP on plasma lipids and BEI I WOO, ALBRINK, MAN 
METHODS
Acute experiments. (i) The effect of short-term administration of TRIPROP was studied in medical students or hospital employees with an age span of 23 to 26 years. All were free from known disease. The effect of a single large dose was assessed in three normal persons. Measurements were made of the plasma FFA,' ,' total fatty acids,2"'8 lipid phosphorus,'7 and total cholesterol1" at about 7:30 A.M. after an overnight fast of approximately twelve hours. Samples were taken at 1, 2, 5¼/2, 8¼2, 12, and 24 hours, exhaled gas samples were obtained for determination of the respiratory quotient and the basal metabolic rate."" Because of the method of gas collection, any degree of hypoventilation or hyperventilation would give rise to a misrepresentation of the actual amount of carbon dioxide produced and oxygen used by the body's overall metabolism. As a result of these uncontrollable factors, the results of the BMR and respiratory quotient measurements in the present study cannot be accepted as unequivocal. Throughout the 24 hours the subjects did not ingest any food but were allowed to have water.
One week later the same measurements were made as on the control day, but after the initial collection of samples, TRIPROP in doses of 0.3 mg. per kilo body weight was administered orally. In addition to the above measurements, at 0, 1, 5X,2, 8Y2, 12 , and 24 hours in one subject and at 0 and 51,2 hours in another, blood samples were obtained for the analysis of the serum butanol extractable iodine (BEI).
(ii) An independent study on the influence of a single dose of TRIPROP on the concentration of the BEI was made on three normal subjects, on a patient with coronary artery disease, and on a nine-month-old baby. CONTROL EXPERIMENTAL FIGURE 2. Plasma cholesterol of four subjects during a control period and during a five-day period of daily administration of 0.3 mg. TRIPROP per kg. body weight. Medication was begun immediately after blood was drawn on experimental day one, and given each subsequent day after the withdrawal of blood for lipid analysis. Chronic experimeitts. Six euthyroid patients with elevated concentrations of serum cholesterol, triglycerides, or both, and one obese myxedematous patient were given TRIPROP in doses varying from 1 to 18 mg. daily. The obese patient was on a calorically restricted diet. The fat intake of the other patients was moderately restricted and did not change throughout the period of study.
In vitro experiments. In order to interpret the BEI'sP in vitro recoveries from serum of several analogues of thyroxine including TRIPROP were conducted. The theoretical BEI was calculated from the known composition of the various compounds and the previously determined BEI of the sera. 
RESULTS
Acutte experintents. Since no definite or consistent changes in concentration of cholesterol, lipid phosphorus, triglycerides, or respiratory quotient were observed during the 24 hours following the ingestion of a single large dose of TRIPROP, such data are not presented. The FFA increased to the same degree with fasting whether or not TRIPROP was given (Fig. 1 ).
This dose of TRIPROP caused a marked increase in BEI within one to five hours, following which the BEI gradually decreased to a point below the pretreatment concentration within 56-94 hours (Table I ). In subject A.M., a more rapid rise occurred when TRIPROP was administered with a regular meal than with a solution of glucose.
Daily administration of TRIPROP for six days caused a considerable reduction of plasma cholesterol to a concentration varying between 62 and 82 per cent of the initial values (see Fig. 2 ). However, the plasma total fatty acids, triglyceride fatty acids, lipid phosphorus, and cholesterol-phospholipid ratios did not exhibit a sufficiently consistent response to the ad- ministration of TRIPROP to permit presentations of data. The rise of FFA was difficult to interpret because of the variability of this fraction during the control period (Fig. 3) . The BEI rose markedly during the six days ( Table 2 ). The basal metabolic rate was variable and open to errors mentioned in methods, but nevertheless it appeared to rise during the administration of TRIPROP (Table 3) . TRIPROP did not exert any definite or consistent influence on either systolic or diastolic blood pressure. The morning pulse rate, however, showed an upward trend. After five daily doses of TRIPROP the various pulse rates were from 14 to 26 beats per minute more than the initial values. All four subjects lost weight on the six-day regimen. In two subjects, as much of a reduction as seven pounds in five days was seen. Mild and transient headaches occurred during the six-day experiment in two subjects, in one of whom the onset of cephalalagia coincided with the onset of menstrual flow, and with temporary increase in perspiration in the other of the two subjects. With these exceptions, TRIPROP in the large dosage given here 440 Volumne 33, June 1961 TRIPROP on plasma lipids and BEI WOO, ALBRINK, MAN did not seem to cause any symptoms of nervousness, jitteriness, irritability, increase in appetite, palpitation, or diarrhea.
Chronic experiments. Table 4 summarizes the serum lipids and BEI's of six euthyroid patients and one myxedematous patient given TRIPROP in various doses. Of the euthyroid patients, four or five patients receiving one or two miligrams of TRIPROP daily had no significant change in cholesterol. The first patient in Table 4 voluntarily lost weight during this period. A decrease in cholesterol happened to coincide with the weight loss as sometimes occurs temporarily. Serum cholesterol concentrations decreased in Table 4 . Only one of the seven patients, C.M., showed a decrease in the cholesterol-phospholipid ratio while receiving TRIPROP. In general, BEI's of the euthyroid patients were in the normal range of 3.3 to 6.4 micrograms per 160 ml. both before and during treatment. Exceptions were the slightly low BEI's before treatment in two patients (A.L. and C.M.); however, at other times these patients had normal BEI's while not receiving medication. There was a tendency for the BEI's to be lower (Table 4) and to be in the upper range of normal, up to 6 pg. per 100 ml., on higher doses. It should be noted that BEI's were determined at least 12 hours after the last medication. Considerably higher values occurred shortly after intake of TRIPROP, as shown in Table 5 . This table shows a normal BEI in the morning when no TRIPROP had been administered for 21 hours, but it shows a high value later in the day, a few hours after the patient had taken her TRIPROP. Forty-eight hours after temporary withdrawal of the drug, the BEI was in the hypothyroid range and the cholesterol had risen to the highest value ever recorded for this patient. She felt rather tired and let down at this time.
All patients lost weight on effective and sometimes on ineffective doses (Table 4) . Patients rarely had resting pulse rates greater than 80 beats; per 444 Volume 33, June 1961 TRIPROP on plasma lipids and BEII WOO, ALBRINK, MAN minute, and none displayed a rise in blood pressure while receiving the drug. Increased perspiration, jitteriness, and easy fatigability were infrequent complaints and noted only during the administration of doses of 6 mg. or greater. Occasionally, faint pruritic rashes were observed but disappeared during the continued treatment. For the most part, there were no subjective symptoms. In addition to the seven patients listed in Table 4 , three obese patients given TRIPROP with the purpose of inducing weight loss did not display any weight-reducing effect from as much as 18 mg. daily. It was necessary for them to restrict calories in the same manner as obese patients not receiving the drug.
In an isolated study not included in the tables, TRIPROP was given for three days in doses of 4 mg. daily to a 28-year-old euthyroid female patient with an enlarged thyroid. Such intake of TRIPROP decreased the uptake of a tracer dose of radioactive iodine from the upper normal range 44S to a borderline low range, and produced an increase in the BEI from 6.1 to 9.0 ,ug. per 100 ml. With continuation of the drug, size of the thyroid gland decreased definitely.
In vitro studies. Recoveries of tetraiodothyropropionic acid, triiodothyroacetic acid, tetraiodothyroacetic acid, triiodothyropropionic acid, and triiodothyronine added in vitro to serum were virtually complete (Table 6 ).
DISCUSSION
The striking reduction of plasma cholesterol following the administration of TRIPROP in the six-day experiment indicates that TRIPROP possesses the cholesterol-lowering action of desiccated thyroid.' Bauer, McGavack, and Swell, in a recent paper, reported that the administration of TRIPROP in a dose of 6 mg. daily to euthyroid adults caused an average reduction in serum cholesterol of 25 per cent after a period of two to four weeks.' However, in the present investigations (Fig. 2) , a dosage of TRIPROP much larger than that used by Bauer, et al. was adopted and correspondingly, the response was observed much sooner. The brevity of the acute experiment prevents prediction of the response of serum cholesterol to a more prolonged treatment with TRIPROP at the constant dose of 0.3 mg. per kilo of body weight.
The long-term administration of TRIPROP to patients with initially elevated serum lipids resulted in a small reduction in concentration of cholesterol when administered in doses varying from 3 to 9 mg. daily. The effectiveness of the drug appeared to depend on a time-dose relationship. If a dose sufficiently great to lower the cholesterol was achieved within four months of initiation of TRIPROP, the cholesterol decreased more than 15 per cent. If an effective dose was reached after six months or longer of gradually increasing small doses, the cholesterol was reduced by less than 10 per cent. The only instance of a marked and sustained reduction in concentration of cholesterol was for the myxedematous patient in whom TRIPROP, in doses from 9 to 18 mg. daily, appeared as adequate as desiccated thyroid in the treatment of hypothyroidism. Possibly smaller doses would have served as well' but large doses were given to encourage weight loss.
Although this series is small, a comparison of the acute experiments, not only with short term experiments of others but also with the long term evaluation of TRIPROP, is compatible with an escape of the cholesterollowering effect of TRIPROP administered to euthyroid persons. Such escape might be expected from the infrequency with which low serum choles-terol concentrations are found in naturally hyperthroid persons although the reverse finding of high cholesterol in hypothyroidism is the rule.'
Escape of the cholesterol-lowering effect of TRIPROP may be accounted for in part by suppression of endogenous thyroid function occurring early after administration of the drug. This suppression was manifest in a single instance by a marked decrease in I' uptake in a patient after three days of receiving TRIPROP; in normal subjects, by a decline in concentration of BEI below pretreatment values three to four days after a single large dose (Table 2) ; and, despite the continued administration of TRIPROP in large doses (Table 2) , by a decrease of the fourth day BEI after an initial rise. Additional evidence for the suppression of endogenous thyroid function was the tendency for BEI's to be low in patients receiving small doses of TRIPROP (Table 4) . A similar phenomenon occurred to a more marked degree in one patient who temporarily stopped the drug and who 48 hours later had a BEI in the hypothyroid range and a marked elevation of her cholesterol ( Table 5) .
The PBI but not the BEI was greatly elevated during administration of TRIPROP. One patient, 49-46-20 ( The evidence presented here is compatible with the thesis that TRIPROP has some of the physiological properties of thyroid to a greater extent than others. Both the cholesterol-lowering and weight-reducing effects of TRIPROP appear to be similar to those of desiccated thyroid. However, the cardiovascular effects of thyroxine were notably absent.
Two of the four patients with previous myocardial infarctions had episodes of myocardial insufficiency while receiving the drug, although the attacks could well have been the result of the disease and not of the drug. Two patients with tendinous and skin xanthomata exhibited progression of their lesions during two years of therapy with the drug, perhaps because effective dosage with regard to its effect on the cholesterol concentration was not maintained during all of this period.
With respect to cholesterol concentrations, the dramatic reduction in the acute experiments was not sustained with prolonged use of the drug. Serum triglycerides, which may be of greater significance than cholesterol in coronary artery disease,8" were not consistently influenced by TRIPROP administration. This accords with the smaller response of low density lipoproteins, the main source of plasma triglycerides, rather than the response of cholesterol to the administration of thyroid hormone, and it is in accord with the usually normal concentration of triglycerides in the sera of hypercholesterolemic hypothyroid patients.'9 The possible therapeutic usefullness of TRIPROP in creating and maintaining an altered in vivo lipid environment cannot be determined on the basis of the present study.
1. The effect of 3,5,3' triiodothyropropionic acid (TRIPROP) on plasma lipids was studied by the administration of this substance to seven normal subjects in a short-term experiment, to six euthyroid patients with elevated lipid concentrations in a long-term study, and to one myxedematous patient. Serum or plasma was analyzed for BEI, cholesterol, FFA, total fatty acids, triglyceride fatty acids, and phospholipids.
2. No consistent effects of TRIPROP on plasma FFA, triglyceride fatty acids, phospholipids, cholesterol, and basal metabolic rate were observed within 24 hours of a single large dose although a marked increase in plasma BEI took place within one to five hours. However, five days of administration of 0.3 mg. per kg. body weight caused a marked decrease in serum cholesterol concentration varying from 18 to 38 per cent. The changes in FFA were equivocal, and the other lipid components did not change. Weight loss occurred in all subjects. The subjective symptoms of thyroid overactivity such as tachycardia, palpitations, and nervousness were absent.
3. The administration of 3 mg. or more of TRIPROP daily to six euthyroid patients with high blood lipids caused a small reduction of serum cholesterol. The decrease was greater than 15 per cent during the first four to six months of treatment only, and was less than 10 per cent with prolonged administration. No consistent effect on triglyceride concentration or the cholesterol-phospholipid ratio was noted. Weight loss occurred in all patients given doses sufficient to lower the cholesterol. Subjective symptoms were absent or minimal.
4. Marked and permanent reduction of all lipid components of serum and restoration of the euthyroid state followed administration of TRIPROP to one myxedematous patient.
